Glucotrack, Inc. and Lōkahi Therapeutics have officially completed their strategic business combination, creating a new, publicly traded entity. This merger establishes a capital-efficient platform dedicated to identifying, acquiring, and advancing differentiated healthcare assets. Under the terms of the agreement, Lōkahi Therapeutics will function as the operating and controlling business of the combined company.
A Strategic Combination for Growth
The newly formed organization integrates Lōkahi Therapeutics' innovative dual-engine model with Glucotrack's established public market platform. This model includes a late-stage clinical development program and an AI-driven system for sourcing and advancing new assets. The synergy is designed to create a scalable and repeatable framework for generating significant value in the biopharmaceutical sector.
Transaction Structure and Financials
As part of the transaction, Lōkahi Therapeutics securityholders received a combination of Glucotrack common and convertible preferred stock. Following necessary stockholder approvals and meeting Nasdaq listing requirements, the preferred stock is set to convert into common equity. This conversion will result in Lōkahi securityholders owning approximately 90% of the combined company on a fully diluted basis.
To support the merger and near-term operational goals, the transaction is backed by a planned private placement financing. This capital injection is intended to significantly strengthen the combined company’s financial position and ensure robust execution of its strategy. A specific portion of the proceeds will be allocated to the continued development of Glucotrack’s legacy glucose monitoring technology.
Leadership and Operational Framework
A new leadership team has been appointed to guide the combined company toward its strategic objectives. Erik Emerson will serve as the Chief Executive Officer, providing unified leadership across the entire organization. Paul Goode has been named Chief Technical Officer of the combined entity and will also act as Chief Executive Officer of the glucose monitoring subsidiary.
Glucotrack’s original continuous blood glucose monitoring (CBGM) business will now operate as a wholly owned subsidiary. Its operations, assets, and capital structure will be maintained separately to allow for focused execution and strategic flexibility. This structure ensures the core technology continues its advancement while being part of a broader, growth-oriented platform.
Vision for the Future
CEO Erik Emerson stated that the transaction establishes a platform designed to systematically advance unique healthcare assets. He emphasized that combining public market access with Lōkahi's disciplined model positions the company to expand its pipeline and pursue new opportunities. This strategic alignment is expected to fortify the company's capital structure for future growth initiatives.
CTO Paul Goode added that the combination facilitates the continued progress of Glucotrack’s core technology within a focused structure. He noted that this integrated approach supports disciplined execution across both the legacy business and the new asset acquisition platform. The structure allows the CBGM technology to benefit from the resources of a larger, scalable growth-oriented company.
This strategic merger marks a significant transformation for both Glucotrack and Lōkahi Therapeutics, launching a new biopharmaceutical platform. By uniting Lōkahi's AI-driven asset acquisition strategy with Glucotrack's public listing, the combined company is uniquely positioned for scalable growth. The new entity is poised to make a substantial impact by advancing overlooked therapeutic assets within the healthcare industry.